• Waquaruddin Ahmed
  • Ambreen Arif
  • Ejaz Alam
  • Huma Qureshi


Background: Sustained virological response to interferon therapy is a great challenge for patients ofchronic Hepatitis C. Over 20 brands of interferons are available in the local market with each claimingover 80% response and a wide variation in the cost thus creating confusion for treating physicians as towhich drug should be selected. Methods: Chronic Hepatitis C patients attending outpatients departmentof Pakistan Medical Research Centre JPMC from January 1998–December 2010 were evaluated.Complete blood count, liver function tests, serum proteins, HCV-RNA were done in all cases beforestarting therapy. Side effects were also noted. Results: Total of 851 cases received interferon 3 MIUthree times a week for 6 months. There were 638 (75%) males and 213 (25%) females, mean age was36.1±10.4 years. All were HCV-RNA positive prior to treatment, at the end of 6 months 666 (78.3%)became negative while 185 (21.7%) were non-responders with positive HCV RNA. End of treatmentresponse (ETR) showed 84.7% with Bioferon (Argentina), 83.8% Hebron (Cuba), 82.2% INF(Argentina), 82.1% Ceron (China), 81% Viteron (Korea), 80.7% Leveron (Argentina), 81.5%Hepaferon, 79.1% Anferon (China), 77.4% Intron (Belgium), 75% Green alpha (Korea), 74% Roferon(Switzerland), 67.3% Uniferon (Lithuania), and 68.4% with others. Post-treatment 211 cases were lost tofollow-up. In remaining 358/640 (55.9%) negative for HCV-RNA, at six months follow up, whereas 98(15.3%) relapsed. Sustained virological response (SVR) Ceron 68.2%, Hebron 66.3%, Bioferon 65.2%,Leveron 60.5%, Intron 60.3%, Viteron 57%, Anferon 53.3%, Green alpha, Roferon, Hepaferon, andothers 50%, INF 48.5% and Uniferon 41.9%. Average cost of these interferons was Rs. 6,000/month,except Hepaferon 5,000/month, Roferon 10,600/month. Conclusions: ETR ranged from 74–84.7% andSVR 41.9% to 68.2% and >60% SVR was observed with Ceron, Hebron, Bioferon, Leveron, Intron andwere cost effective.Keywords: Conventional interferon, response, chronic Hepatitis C.


Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HUR. Prevalence

of hepatitis B and C viral infections in Pakistan: findings of a

national survey appealing for effective prevention and control

measures. East Mediterr Health J 2010;16 Suppl:S15-23.

Ahmed W, Qureshi H, Arif A, Alam SE. Changing trend of viral

hepatitis –A twenty-one year report from Pakistan Medical

Research Council, Research Centre, Jinnah Postgraduate Medical

Centre, Karachi. J Pak Med Aassoc 2010:60(2):86–9.

Rehman I, Idrees M, Ali M, Ali L, Butt S, Hussain A, et al.

Hepatitis C virus genotype 3a with phylogenetically distinct

origin is circulating in Pakistan. Genet Vaccines Ther 2011;9:2.

Farooqi JI, Farooqi RJ. Efficacy of conventional Interferon alpha-

b plus Ribavirin combination in the treatment of Chronic

Hepatitis C naïve patients. Rawal Med J 2005;30:9–11.

Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A,

Peters M, et al. Treatment of chronic non-A, non-B hepatitis with

recombinant human alpha interferon. A preliminary report. N

Engl J Med 1986;315:1575–8.

Tong MJ, Blatt IM, McHutchison JG, Co RL, Conrad A.

Prediction of response during interferon alfa 2b therapy in

chronic hepatitis C patients using viral and biochemical

characteristics: A comparison. Hepatology 1997;26:1640–5.

Ferrell GC, Bacon BR, Goldin RD. Lymphoblastoid Interferon

alfa-n1 improves the long term response to a 6-month course of

treatment in chronic hepatitis C compared with recombinant

interferon alfa-2b: Results of an international randomised

controlled trial, Clinical Advisory Group for the Hepatitis C

Comparative study. Hepatology 1998;27:1121–7.

McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee

WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination

with Ribavirin as initial treatment for chronic hepatitis C.

Hepatitis Interventional Therapy Group. N Engl J Med


Devis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo

C, et al. Interferon alfa-2b alone or in combination with Ribavirin

for the treatment of relapse of chronic hepatitis C. International

Hepatitis Interventional Therapy Group. N Engl J Med


Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid M, Hoofnagle

JH. 10-years follow-up after interferon-alpha therapy for chronic

hepatitis C. Hepatology 1998;28:1121–7.

Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung

SN, Seef LB. Tolerance and efficacy of oral Ribavirin treatment

of chronic hepatitis C: a multicenter trial. Hepatology


J Ayub Med Coll Abbottabad 2012;24(3-4) 123

Kjaergard LL, Krogsgaad K, Gluud C. Interferon alfa with or

without Ribavirin for chronic hepatitis C: systematic review of

randomised trials. BMJ 2001;323:1151–5.

Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al.

Long-term efficacy of Ribavirin plus interferon alfa in the

treatment of chronic hepatitis C. Gastroenterology


Pol S, Nalpas B, Bourliere M, Couzigou P, Tan A, Abergel A, et

al. Combination of Ribavirin and interferon-alfa suppresses high

dose of interferon-alfa alone in patients with genotype-1b related

chronic hepatitis C. Hepatology 2000;31:1338–44.

Tayyab GN, Haque I, Zafar S. Rapid virological response (RVR)

and early virological response (EVR) with standard Interferon

and Ribavirin for chronic HCV infection —An experience. J Pak

Med Assoc 2007;57:S-2.

Ahmed W, Qureshi H, Arif A, Ather R, Kiran. Is response of

Alpha 2A and 2B interferon same in Hepatitis C. J Pak Med

Assoc 2007;57:S-14.

Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis,

management and treatment of hepatitis C. AASLD practice

guidelines 2004. Available at: http//

AASLD_Prac_Guide HepC.pdf

Hamid S, Umar M, Alam A, Siddiqui A, Qureshi H, Butt J.

Pakistan Society of Gastroenterology. PSG Consensus Statement

on management of Hepatitis C virus infection 2003. J Pak Med

Assoc 2004;54:146–50.